IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study) (IMPACT)
A Phase IIa, Randomized, Double-blind, Dose Comparison, Placebo-controlled, Multi-centre Clinical Trial to Evaluate the Immune Signature of the Treatment With the Imotope IMCY-0098 and Its Effect on the Preservation of Beta-cell Function in Adult Patients With a Recent Onset Type 1 Diabetes
Sponsor: Imcyse SA
Terminated
No efficacy at primary analysis after 1 year. Long term follow-up stopped
Other terminated trials from Imcyse SA
More terminations from Imcyse SA
Other Diabetes Mellitus, Type 1 trials with similar outcome
A PHASE2 clinical study on Diabetes Mellitus, Type 1, this trial is terminated or withdrawn. The trial is conducted by Imcyse SA and has accumulated 12 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Sep 2022 — Apr 2023 [monthly]
Recruiting PHASE2
-
Dec 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE2
Phase: PHASE1_PHASE2 → PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Imcyse SA
For direct contact, visit the study record on ClinicalTrials.gov .